[Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].

Tomohisa Egawa, Takeshi Kemmochi, Tomoyuki Irino, Koki Mihara, Akihiko Okamura, Eiichi Etoh, Yusaku Inaba, Kenki Segami, Yasuhiro Ito, Atsushi Nagashima

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Adjuvant chemotherapy with S-1 monotherapy might be insufficient for Stage IIIB highly advanced gastric cancer patients. Our retrospective study was to evaluate the feasibility and safety of adjuvant chemotherapy with S-1 plus docetaxel. S-1 (80 mg/m2) was administered orally for 2 weeks then followed by a 1-week rest period. Docetaxel (40 mg/m2) was simultaneously administered on day 1. The treatment was administered for 1 year and began 6 weeks after D2 curative surgery. Five patients tolerated adjuvant chemotherapy with S-1 plus docetaxel for 1 year (17 courses of treatment). Grade 3/4 hematological toxicities were observed in 10% patients (n=1). Grade 3/4 non-hematological toxicities were observed in 20% patients (n=2). We concluded that S-1 plus docetaxel as adjuvant chemotherapy is a promising strategy for patients with highly advanced gastric cancer.

Original languageEnglish
Pages (from-to)2310-2312
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number12
Publication statusPublished - 2012 Nov
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of '[Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].'. Together they form a unique fingerprint.

Cite this